In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ultragenyx starts Series A round with $30mm; adds on $15.1mm later

Executive Summary

Ultragenyx Pharmaceutical Inc. (orphan disease therapeutics) raised $30mm through the start of its Series A round. TPG Biotech and Fidelity Biosciences co-led and were joined by HealthCap, Pappas Ventures, and four other investors. TPG, Fidelity, and HealthCap have all taken seats on the company’s board. According to the Form D, Ultragenyx hopes to raise another $15mm before closing out the round.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies